Dr. Everhart is an innovator, educator, and leader in the pharmaceutical and biotechnology industries with over 25 years of experience in the practice of medicine and over 14 years of experience in clinical research.  Board-certified in Internal Medicine and a Fellow of the American College of Physicians, he is one of Signant Health’s experts in decentralized trials, rater training, blinded data analytics, and placebo response mitigation. 

Dr. Byrom has worked in the pharmaceutical industry for 30 years. He has authored over 70 publications and two industry textbooks on electronic patient-reported outcomes (ePRO). His recent scientific work includes the use of wearable technology and bring-your-own-device (BYOD) eCOA in clinical trials

Dr. Fredane serves as the Therapeutic Area Leader for neurology, overseeing Signant’s eCOA, rater training, and quality assurance work. He has experience as a practicing neurologist, clinical assistant professor, and in the drug development for over 15 years.

Dr. Busner has over 35 years of experience as an academic psychiatric researcher and psychopharmacology principal investigator, and founded and directed two university psychiatric clinical trials units. Dr. Busner served continuously on University Institutional Review Boards for 20 years. At Signant she has scientific and clinical responsibility for studies in mood, anxiety, pediatrics, and rare/orphan diseases. She has overseen hundreds of trials and trained thousands of raters. Dr. Busner is currently Affiliate Associate Professor of Psychiatry at Virginia Commonwealth University.

Dr. Sachs is the Therapeutic Area Leader in bipolar disease and mood disorders at Signant. He lends his extensive experience in rater training and the methodologies of mood and anxiety disorder research to support studies. 

Dr. Daniel has over 25 years of experience overseeing rater training and data quality management programs in various settings. He has supervised countless clinical trials for schizophrenia and bipolar disorder. In addition to his work with Signant, David serves as Clinical Professor of Psychiatry at George Washington University. 

Dr. Kott is based in Signant’s Prague office and until recently was Senior Clinical Manager for Europe. Having led the development of the Data Analytics Program for Bracket, he has overseen the design and reporting of data analytics in multiple large schizophrenia studies. For the past seven years, he has also provided training to investigators as an Expert Trainer.

Dr. Bart is both Board certified and a Certified Physician Investigator with a broad therapeutic scope including successful completion of more than 450 domestic and international phase 1 through 3 human clinical trials. He has maintained a successful private practice, held faculty positions at Penn State University and the University of Maryland Medical Center, as well as published many articles in prestigious peer reviewed journals. Dr. Bart is an industry key opinion leader in several areas, with extensive focus on advancing vaccine and immunology research over the past decade. 

Dr. Miller is a geriatric psychiatrist by training. He has over 25 years of experience in patient care, clinical research, teaching, and even served as a principal investigator for dementia studies. David currently serves as the Chair of the Alzheimer’s Association Research Roundtable.

A board-certified psychiatrist, Dr. Frakes has extensive experience in central nervous system clinical drug development. He has served as the medical monitor and scientific advisor on numerous clinical trials for indications that include Alzheimer’s, multiple sclerosis, epilepsy, depression, anxiety, bipolar disorder, schizophrenia, ADHD, alcohol abuse and a variety of pain syndromes.

Dr. Bossi has authored numerous articles on vision neuroscience, focusing on human binocular vision and perception. From questionnaire creation and administration to data best practices and consent, Manuela’s clinical research experience within academic and NHS institutions will guide researchers through trial challenges.

Dr. de Waal provides scientific consultation to clients relating to the implementation of electronic clinical outcome assessments. Dr. de Waal has 2+ years’ experience in the clinical research industry, previously forming part of a Medical Strategy team. She has been supporting projects across a wide variety of therapeutic areas, including oncology, infectious disease, and dermatology. 

Dr. Kusanto studied bioengineering at Oregon State University before completing his PhD in platelet biology at Hull York Medical School. At Signant, he specializes in eCOA, eConsent, and multiple therapeutic areas like, dermatology, gastroenterology, pediatrics, and rare diseases.